z-logo
open-access-imgOpen Access
<p>Response to Anti-HER2-Based Treatment in a Patient with Bladder Adenocarcinoma Harboring <em>HER2</em> Amplification and S310F Mutation Discovered by Next-Generation Sequencing: A Case Report</p>
Author(s) -
Xiaolu Wang,
Weixin Hu,
Li Xie
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s247515
Subject(s) - trastuzumab , medicine , adenocarcinoma , oncology , bladder cancer , targeted therapy , mutation , dna sequencing , metastasis , cancer research , cancer , gene , biology , breast cancer , biochemistry
HER2 overexpression has been identified in approximately 14% of bladder adenocarcinomas. However, until now, there has been no approved standard targeted therapy for bladder adenocarcinoma patients harboring HER2 genetic alteration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here